Best-in-Class

• Oncology

  A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC 【Product for Licensing】

  If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn

  2024年11月12日

  1.2K0